CPNP Symposium: Achieving and Maintaining Improved Quality of Life in Patients with Tardive Dyskinesia

CPNP Symposium: Achieving and Maintaining Improved Quality of Life in Patients with Tardive Dyskinesia

On-Demand Webcast

This session was recorded live during the 2020 CPNP virtual conference. If you claimed credit for the live ISS session, you are not eligible to claim credit for this on-demand. 

FACULTY

Christoph U. Correll, MD
Professor of Psychiatry
Zucker School of Medicine at Hofstra/Northwell
Floral Park, New York

Stephen R. Saklad, PharmD, BCPP
Clinical Professor and Director of Psychiatric Pharmacy
The University of Texas at Austin
College of Pharmacy, Pharmacotherapy Division
San Antonio, Texas

PROVIDER STATEMENT

Provided by North American Center for Continuing Medical Education, LLC, an HMP Company.

For questions regarding this educational activity, please call 609-371-1137 or email info@naccme.com.

INTENDED LEARNERS

This activity is designed for psychiatric pharmacists.

LEARNING OBJECTIVES

After participating in this activity, participants should be better able to:

  • Outline the consequences of untreated TD on QoL in patients taking antipsychotic medications
  • Describe the clinical indications for and clinical benefits of administering the AIMS exam
  • Overcome barriers that interfere with patient adherence to VMAT2 inhibitors for the treatment of TD in order to improve patient QoL
CLAIMING CREDIT

To be eligible for credit, participants must complete the online activity, a post-test assessment, and the evaluation by May 1, 2021. Upon completing the activity, there will be instructions on how to print a certificate or other documentation of credit.

Release Date: May 1, 2020
Expiration Date: May 1, 2021
Estimated Time to Complete: 1.5 hours

There is no fee associated with this activity.

COMMERCIAL SUPPORT

NACCME would like to thank the following company/companies who has/have supported the "Achieving and Maintaining Improved Quality of Life in Patients with Tardive Dyskinesia" through educational grants and/or in-kind support: Neurocrine Biosciences and Teva Pharmaceuticals

CONTINUING EDUCATION

 In support of improving patient care, NACCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

PHARMACY

This on demand, knowledge-based activity (Universal Activity Number JA0006201-0000-20-161-H01-P) has been approved for a maximum of 1.5 contact hours (0.15 CEUs).

The certificate is not the official record of your participation in the activity. The official record of credit will be the information in CPE Monitor system. The deadline to claim credit is 60 DAYS AFTER THE ACTIVITY. Following ACPE Policy, NACCME will not be able to report your claimed credit to CPE Monitor after this 60-day period. Eligibility for pharmacy credit is contingent upon the successful completion of a post-test and/or evaluation for each activity or session attended.

Any participant wanting to file a grievance with respect to any aspect of a continuing education activity accredited by NACCME, LLC may contact Samantha Conforti, Manager, Accreditation and Compliance, by phone at 609-371-1137, by email at sconforti@naccme.com or in writing at 104 Windsor Center Drive, East Windsor, NJ 08520. The Manager, Accreditation and Compliance will review the grievance and respond within 30 days of receiving the complaint. If the participant is unsatisfied with the response, an appeal to the Senior Manager/Director or the Executive Vice President, Chris Bolwell, Accreditation and Compliance, can be requested for a second level of review. Mr. Bolwell can be contacted via phone at 678-242-0801, by email at c.bolwell@imedex.com or in writing at 11675 Rainwater Drive, Suite 600 Alpharetta, GA 30009

PSYCHOLOGISTS

As a Jointly Accredited Organization, North American Center for Continuing Medical Education, LLC (NACCME) is approved by the American Psychological Association to sponsor continuing education for psychologists. NACCME maintains responsibility for this program and its content. Variable credit for partial attendance may not be awarded. Full attendance is required for all CE activities.

Instructional Level: Advanced

This activity will award 1.5 continuing education credits.

USE OF PROPRIETARY NAMES

This continuing medical education activity may include device or medicine brand names for participant clarity purposes only, due to the presence of different branded versions of the same product. No product promotion or recommendation should be inferred.

UNAPPROVED AND/OR INVESTIGATIONAL USES OF DRUGS AND DEVICES

This activity may contain information about experimental and other uses of drugs or devices that are not currently approved by the European Medicines Agency (EMA) of the European Union or the Food and Drug Administration (FDA) of the United States. Participants are strongly encouraged to consult approved product labeling for any drug or device mentioned in this activity before use. The opinions expressed during this activity are the opinions of the respective authors, presenters or moderators and do not necessarily reflect the opinions of NACCME.

DISCLAIMERS

The material presented and related discussions are not intended to be medical advice, and the presentation or discussion of such material is not intended to create and does not establish a physician-patient relationship. Medical advice of any nature should be sought from an individual’s own physician.

Neither NACCME nor any of its subsidiaries or affiliates is affiliated with, or formally endorsed by a medical society.

The opinions expressed in this educational activity are those of the faculty and are not attributable to NACCME or HMP. Clinical judgment must guide each professional in weighing the benefits of treatment against the risk of toxicity. Dosages, indications, and methods of use for products referred to in this activity are not necessarily the same as indicated in the package insert for each product, may reflect the clinical experience of the presenters, and may be derived from the professional literature or other clinical sources. Consult complete prescribing information before administering.

DISCLOSURE OF RELEVANT FINANCIAL RELATIONSHIPS

NACCME, LLC is an independent provider(s) of continuing medical education. NACCME, LLC has no proprietary or financial interest in medical or healthcare products over which the FDA (USA) or EMA (EU) has regulatory authority.

NACCME, LLC assures that all educational materials are reviewed to ensure for the absence of commercial bias, fair balance, scientific objectivity, and levels of evidence. The educational activity will not be influenced by commercial organizations and will not conflict with any other scheduled educational activities.

According to the disclosure policy of NACCME, faculty, editors, managers, and other individuals who are in a position to control content are required to disclose any relevant financial relationships with relevant commercial companies related to this activity. All relevant conflicts of interest that are identified are reviewed for potential conflicts of interest. If a conflict is identified, it is the responsibility of NACCME to initiate a mechanism to resolve the conflict. The existence of these interests or relationships is not viewed as implying bias or decreasing the value of the presentation.

Clinical Reviewers

William C. Torrey, MD
Professor and Vice Chair for Clinical Services
Dartmouth’s Geisel School of Medicine Dartmouth-Hitchcock
Lebanon, New Hampshire

Nurse Planner: Susie Seaman, NP, MSN, CWOCN, Infectious Disease Consultants/San Diego Infusion Center, San Diego, CA

Planning Committee

In addition to the faculty listed below, NACCME planners and staff include Chris Bolwell, Sam Conforti, Mary Johnson, Randy Robbin, Horacio Rodriguez, and Margie Stefan.

Chris Bolwell is a shareholder of GlaxoSmithKline. GlaxoSmithKline is not supporting this activity, nor does any content relate to their product/service.

Faculty

The faculty has reported the following:

Dr. Correll: Grant/Research Support—Janssen, Takeda; Consultant—Alkermes, Allergan, Angelini, Boehringer-Ingelheim, Gedeon Richter, Gerson Lehrman Group, Indivior, IntraCellular Therapies, Janssen/J&J, LB Pharma, Lundbeck, MedAvante-ProPhase, Medscape, Merck, Neurocrine, Noven, Otsuka, Pfizer, Recordati, Rovi, Servier, Sumitomo Dainippon, Sunovion, Supernus, Takeda, and Teva

Dr. Saklad: Grant/Research Support—Alkermes; Consultant: Alkermes, Genomind, Intracellular Therapeutics; Speakers’ Bureau—Alkermes, Neurocrine

Ms. Seaman: Speakers’ Bureau—Next Science

Dr. Torrey has disclosed no relevant financial relationships with any commercial interests.

ADA STATEMENT

North American Center for Continuing Medical Education (NACCME) complies with the legal requirements of the Americans with Disabilities Act and the rules and regulations thereof. If any participant in this educational activity is in need of accommodations, please call 609-371-1137.

PRIVACY POLICY

NACCME protects the privacy of personal and other information regarding participants, educational partners, and joint providers. NACCME and our joint providers will not release personally identifiable information to a third party without the individual’s consent, except such information as is required for reporting purposes to the appropriate accrediting agency. NACCME maintains physical, electronic, and procedural safeguards that comply with federal regulations to guard your nonpublic personal information.

Copyright © 2020 by North American Center for Continuing Medical Education, LLC. All rights reserved. No part of this accredited continuing education activity may be reproduced or transmitted in any form or by any means, electronic or mechanical, without first obtaining permission from North American Center for Continuing Medical Education.